Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Yen Charles, Fevzi Altuntaş et al.|The Lancet Oncology|2019

Cited by 383